Sonnet BioTherapeutics - SONN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.00
  • Forecasted Upside: 1,718.18%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.65
▲ +0.15 (10.00%)

This chart shows the closing price for SONN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sonnet BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SONN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SONN

Analyst Price Target is $30.00
▲ +1,718.18% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Sonnet BioTherapeutics in the last 3 months. The average price target is $30.00, with a high forecast of $30.00 and a low forecast of $30.00. The average price target represents a 1,718.18% upside from the last price of $1.65.

This chart shows the closing price for SONN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Sonnet BioTherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2024Chardan CapitalLower TargetBuy ➝ Buy$75.00 ➝ $30.00Low
11/27/2023LADENBURG THALM/SH SHInitiated CoverageBuyLow
8/16/2023Chardan CapitalLower TargetBuy ➝ Buy$308.00 ➝ $264.00Low
5/10/2023Chardan CapitalLower Target$374.00 ➝ $308.00Low
4/19/2023EF Hutton Acquisition Co. IReiterated RatingBuy$147.40Low
4/19/2023Chardan CapitalLower TargetBuy$484.00 ➝ $374.00Low
2/15/2023EF Hutton Acquisition Co. IReiterated RatingBuy$147.40Low
12/19/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$147.40Low
9/22/2022Chardan CapitalBoost TargetBuy ➝ Buy$484.00Low
8/16/2022Chardan CapitalLower TargetBuy$770.00 ➝ $616.00Low
2/9/2022BTIG ResearchLower TargetBuy$1,540.00 ➝ $616.00High
12/20/2021Chardan CapitalLower TargetBuy$2,464.00 ➝ $770.00High
12/16/2021HC WainwrightInitiated CoverageBuy$616.00High
9/15/2021BTIG ResearchInitiated CoverageBuyHigh
9/3/2020Chardan CapitalBoost TargetPositive ➝ Buy$2,156.00 ➝ $2,464.00Medium
8/16/2020Chardan CapitalReiterated RatingBuy$2,156.00Low
6/25/2020Chardan CapitalReiterated RatingBuy$2,156.00Low
6/5/2020Chardan CapitalInitiated CoverageBuy$2,156.00High
(Data available from 5/27/2019 forward)

News Sentiment Rating

-0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/26/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/26/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sonnet BioTherapeutics logo
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $1.65
Low: $1.59
High: $1.71

50 Day Range

MA: $1.87
Low: $1.50
High: $2.26

52 Week Range

Now: $1.65
Low: $1.08
High: $26.40

Volume

21,800 shs

Average Volume

74,643 shs

Market Capitalization

$5.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Sonnet BioTherapeutics?

The following Wall Street research analysts have issued research reports on Sonnet BioTherapeutics in the last year: Chardan Capital, and LADENBURG THALM/SH SH.
View the latest analyst ratings for SONN.

What is the current price target for Sonnet BioTherapeutics?

1 Wall Street analysts have set twelve-month price targets for Sonnet BioTherapeutics in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 1,718.2%. Chardan Capital has the highest price target set, predicting SONN will reach $30.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $30.00 for Sonnet BioTherapeutics in the next year.
View the latest price targets for SONN.

What is the current consensus analyst rating for Sonnet BioTherapeutics?

Sonnet BioTherapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SONN will outperform the market and that investors should add to their positions of Sonnet BioTherapeutics.
View the latest ratings for SONN.

What other companies compete with Sonnet BioTherapeutics?

How do I contact Sonnet BioTherapeutics' investor relations team?

Sonnet BioTherapeutics' physical mailing address is 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540. The company's listed phone number is 609-375-2227 and its investor relations email address is [email protected]. The official website for Sonnet BioTherapeutics is www.chanticleerholdings.com. Learn More about contacing Sonnet BioTherapeutics investor relations.